10-Q: Cancer Capital Corp. Reports Continued Losses in Q2 2024, Going Concern Uncertainty Remains

Cancer Capital Corp.'s Q2 2024 filing reveals ongoing losses, minimal cash reserves, and continued reliance on related-party funding, raising substantial doubt about its ability to continue as a going concern.

Summary

• Cancer Capital Corp. filed its Form 10-Q for the quarter ended June 30, 2024.
• The company has not recorded any revenues since its inception and is dependent on financing to continue operations.
• For the six months ended June 30, 2024, the net loss was $25,775, compared to $20,016 for the same period in 2023.
• Cash reserves are low, with $5,157 on hand as of June 30, 2024, a decrease from $16,157 at the end of 2023.
• Total liabilities increased to $480,325 as of June 30, 2024, from $465,549 at the end of 2023.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• Management intends to pursue a business combination to generate revenue.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of personnel for segregation of duties.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the company's ongoing losses, minimal cash reserves, going concern uncertainty, and ineffective disclosure controls.

Positives

• Management intends to pursue a business combination to generate revenue.

Negatives

• The company has not recorded revenues since inception.
• The company has incurred losses since inception.
• The company has negative cash flows from operations.
• The company has limited assets.
• The company is dependent on financing to continue operations.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of personnel for segregation of duties.

Risks

• The company's independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.
• The company's plan to combine with an operating company may involve a financially unstable or early-stage entity.
• A business combination will likely result in a significant issuance of shares and substantial dilution to present stockholders.
• The selection of a business opportunity will be complex and extremely risky.
• The company may need to raise additional capital, which could dilute existing stockholders.
• The company's disclosure controls and procedures were deemed ineffective due to a lack of personnel for segregation of duties.

Future Outlook

Management intends to pursue a business combination to generate revenue and believes it can meet its obligations through funds provided by management, significant stockholders, and/or third parties.

Management Comments

• Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements.
• Our plan is to combine with an operating company to generate revenue.

Industry Context

Given the company's lack of revenue and dependence on related-party funding, it is likely operating in a high-risk sector, possibly involving early-stage ventures or turnaround situations. The company's strategy of seeking a business combination is a common approach for shell companies or entities seeking to revitalize their operations.

Comparison to Industry Standards

• It is difficult to compare Cancer Capital Corp.'s performance to industry standards due to its lack of revenue and unique situation.
• Many shell companies or companies seeking a turnaround may exhibit similar financial characteristics, such as low cash reserves and reliance on external funding.
• The success of Cancer Capital Corp. hinges on its ability to identify and execute a successful business combination, which is a high-risk endeavor.

Related Party Transactions

• During the six months ended June 30, 2024, a shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs provided or paid on behalf of the Company totaling $3,000 and $1,500, respectively, resulting in the Company owing the shareholder $9,000 and $6,000 at June 30, 2024 and December 31, 2023, respectively.
• A shareholder loaned the Company funds in prior years, with notes bearing interest at 8% and due on demand.
• Notes payable related party at June 30, 2024 and December 31, 2023 were $164,125 and $164,125, respectively.
• Accrued interest at June 30, 2024 and December 31, 2023 was $96,718 and $90,153, respectively.

Stakeholder Impact

• Shareholders may experience dilution if the company issues more shares of common stock.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.
• The company's plan to combine with an operating company may involve a financially unstable or early-stage entity, which could impact stakeholders.

Next Steps

• The company intends to find a suitable business opportunity and acquire or enter into a merger with such company.
• The company anticipates incurring additional costs related to the filing of Exchange Act reports.
• The company may rely on the issuance of its common stock in lieu of cash to convert debt or pay for expenses.

Key Dates

Keywords

financial statements, going concern, net loss, related party transactions, liquidity, capital resources, business combination, Cancer Capital Corp